72 results about "Endostelium" patented technology

The present invention relates to determining the receptivity of human endometrium from a gene expression profile. More specifically, the invention consists of developing a specific expression microarray of endometrial receptivity (Endometrial Receptivity Array or ERA) which allows evaluating the receptive state of a human endometrium, as well as assessing said state for diagnostic and therapeutic purposes.

The invention discloses a protein extraction and treatment process at different time points (including early, middle and late periods of secretion: LH_2, LH_5, LH_7, LH_9, LH_10 and LH_12, and LH_0 on the day of injection of hCG) in a human endometrial tissue secretion period, and a protein spectrum and a phosphorylation modification mass spectrum are carried out to obtain molecular expression modes at different time points in the secretion period. The molecular expression modes can provide a basis for further knowing the dynamic change of the human endometrial tissue secretion period, and is beneficial to judging an endometrial implantation window period and guiding the embryo transplantation time in an assisted reproduction technology.

The invention discloses traditional Chinese medicine for treating thin endometrium. The traditional Chinese medicine is mainly prepared from radix codonopsis, semen euryales, cornu cervi degelatinatum, fructus psoraleae, herba cistanches, rhizoma dioscoreae, pulp of cornus, radix salviae miltiorrhizae, caulis spatholobi, common ginger, trogopterus dung processed with wine and radix glycyrrhizae preparata. The formula composed of raw material medicine tonifies the kidney, activates blood, replenishes essence and cultivates cells, therefore, thickness of endometrium of females is enhanced, the menstrual blood volume is increased, capability of gestating babies of females is improved, and clinical treatment efficiency of the traditional Chinese medicine is 97.78%.

The present invention relates to a method for assessing the endometrium receptivity of a patient, comprising a step consisting of measuring the expression level of eleven genes in an endometrial biopsy sample obtained from said patient wherein said genes are MFAP5, ANGPTL1, PROK1, NLF2, LAMB3, BCL2L10, CD68, TRPC4, SORCS1, FST and KRT80.

The invention discloses an endometrium sampling device and belongs to the field of medical apparatus and instruments. The endometrium sampling device comprises a lead-in pipe and a sleeve core, the lead-in pipe is arranged on the sleeve core in a sleeving mode, the front end of the sleeve core is provided with a plug, the tail end of the sleeve core is provided with a sleeve core holding handle, the front end of the sleeve core is provided with an anti-twist sampling segment, and the anti-twist sampling segment is fixedly connected with the plug. The endometrium sampling device is uniform in sampling, a reliable diagnosis result can be obtained, the pain of a patient is reduced, and endometrium sampling device has good application and popularization value.

Disclosed herein are compositions and methods useful for the diagnosis, assessment, and characterization of endometriosis in a subject in need thereof, based upon the expression level of at least onemiRNA that is associated with endometriosis.

The invention belongs to the technical field of medicine, and particularly discloses a composition for improving thin endometrium and a preparation method and application thereof. The composition is prepared from stem cell culture supernatant and vitamin E. After the composition for improving thin endometrium is used, expression of VEGF and integrin beta 3 in endometrium can be enhanced, the thickness of endometrium is increased, and uterus receptivity and blood supply are improved.

The invention relates to detection of individuals having or at risk of developing endometriosis based on the presence of one or more polymorphism in a gene associated with the fibrinolytic pathway, and methods for treating or preventing endometriosis by modulating the fibrinolytic pathway.

The invention discloses application of cyanidin-3-O-glucoside in preparation of a medicine for treating and/or preventing an endometrial hyperplasia disease. The cyanidin-3-O-glucoside is found to becapable of improving endometrial hyperplasia and endometrial hyperproliferation caused by Cd exposure, and the cyanidin-3-O-glucoside intervenes in the process of protecting growth and development ofendometrial cells by maintaining the estrogen effect level, so that the uterus can normally grow, embryo implantation is ensured, and meanwhile, the cyanidin-3-O-glucoside has a protection effect on the endometrium. Therefore, the cyanidin-3-O-glucoside has a good application prospect in preparation of the medicine for treating and/or preventing the endometrial hyperplasia disease, preparation ofthe medicine for treating and/ or preventing Cd-induced abnormal proliferation of the endometrial cells and preparation of the medicine for protecting the endometrium.

The invention discloses an automatic segmentation typing and thickness measuring method based on an endometrial ultrasound image, which comprises the following steps: 1) collecting an endometrial ultrasound scanning image set, manually selecting a standard uterus longitudinal cutting image, sketching an endometrial boundary, making a typing label, and establishing a training and testing sample set; 2) carrying out image preprocessing such as filtering on each image; removing noise influence and achieving an image enhancement effect; 3) respectively constructing a deep learning model for segmenting an endometrial region and typing, and respectively inputting a training set for training; 5) performing the same image preprocessing on the test set image, inputting the test set image into the trained deep learning model, and performing segmentation to obtain a segmented endometrial region and a typing result; 6) calculating the thickness of the endometrium by using a digital image morphological algorithm and a segmentation result of the endometrium ultrasonic image; by means of the method, the endometrial area can be accurately and effectively extracted, and more accurate thickness measurement and endometrial typing can be achieved.

The invention discloses an endometrium thickness automatic measurement method and system based on wavelet transform, and relates to an endometrium thickness automatic measurement method based on wavelet transform, which comprises the following steps: S1, receiving an acquired standard longitudinal cutting image corresponding to an endometrium; S2, preprocessing the received endometrium image to obtain a preprocessed endometrium image; S3, performing endometrial image segmentation on the preprocessed endometrial image based on multi-resolution fast wavelet transform to obtain a segmented endometrial image; and S4, according to the obtained segmented endometrium image, automatically measuring the maximum distance between the endometrium basal layers, namely the thickness of the endometrium.According to the image segmentation method based on wavelet transform, the endometrium image is accurately segmented, and the endometrium thickness is automatically measured to serve as a clinical diagnosis basis. The process does not need human intervention, and an automatic measurement result can be quickly and effectively output.

The invention provides a culture medium of endometrial organ and a culture method. The culture medium is prepared from the following components according to final concentration: EGF with the concentration of 10 to 100 ng/ml, Noggin with the concentration of 20 to 500 ng/ml, R-spondin 1 with the concentration of 20 to 500 ng/ml, Wnt3a with the concentration of 20 to 500 ng/ml, FGF9 with the concentration of 1 to 100 ng/ml, KIAA1199 with the concentration of 10 to 200 ng/ml, sox2 with the concentration of 1 to 100 ng/ml, isoflavone with the concentration of 10 to 100 nM, CHIR99021 with the concentration of 100 to 2000 nM, A83-01 with the concentration of 1 to 40 [mu] M, a ROCK inhibitor with the concentration of 2 to 50 [mu] M and primary cell antibiotic with the concentration of 50-200 [mu]/ml; and all the components are dissolved in a DMEM/F12 culture solution. When the culture medium is used for culturing endometrial organ, rapid amplification of endometrial stem cells and maturation and differentiation of the organ are facilitated, the number of passage times is remarkably increased, and the same tissue structure and genome characteristics of primary tissues can still be maintained after multiple passage times.

The invention discloses a bionic endometrium and a preparation method thereof. The bionic endometrium comprises two groups of BAMs (bionic amnions) in mirror symmetry, an ESC (endometrial stromal cells) is arranged between the two groups of BAMs, and according to the bionic endometrium and the preparation method thereof, the ESC is arranged between the two groups of BAMs in mirror symmetry. The BAM is formed in a sandwich structure mode, the hAAM on the two outer layers is provided with a double-layer basement membrane, rich natural fiber tissues are contained in the basement membrane, so that the mechanical strength of the membrane is improved, and the performance of converting the membrane into the endometrium is improved. Sufficient biomechanical strength close to the mechanical property of a fresh amnion can be formed through reinforcement from the front and rear aspects, and in addition, under the fixing action of clamping of the double-layer hAAM and field planting fusion of the hAMSCs, better tensile strength, elasticity and extension property are achieved.

The invention provides an endometrial polyp methylation marker combination for the first time. The endometrial polyp methylation marker combination comprises the following gene markers: IGF1R, CTBP1, TCF7L1, E2F3, CACNA2D4, KCNJ12, TPO, UGT1A8, UGT1A10, CABP5, CST9, ITGA2, DLGAP2, ESPNP, NBPF25P, RASA3, ZIM2, PXDN, HDAC4 and VAV2; the endometrial polyp can be effectively diagnosed by detecting the methylation level of the gene markers in a sample to be detected from a subject, the specificity reaches 87.27%, and the sensitivity reaches 91.11%.

The invention provides a purpose of a pulse-activating decoction to preparation of medicines for improving endometrium. The pulse-activating decoction is a preparation prepared from active componentsof medicinal powder of radix codonopsis, radix ophiopogonis and Chinese magnoliavine fruits, or an aqueous solution of the medicinal powder or an organic solvent extract, and pharmaceutically acceptable auxiliary materials. The pulse-activating decoction is used for assisting in increasing the menstrual blood volume of a patient suffering from thin endometrium (syndromes of deficiency of both qi and yin), the constitutions of qi deficiency, yang deficiency and yin deficiency of the patient suffering from thin endometrium are improved, the thermal metabolism problem of cold wombs of the patientsuffering from the thin endometrium is solved, and the pulse-activating decoction has practical application and promotion value.

The invention relates to the technical field of biological medicines, in particular to application of miR-663a or a target gene CKDN2A thereof in thin endometrium. The invention discloses application of a reagent for detecting the expression level of miR-663a or a target gene CKDN2A of the miR-663a in preparation of a product for detecting thin endometrium. Furthermore, the invention further discloses a biological agent for relieving or repairing the hypoxia injury EEC and application of the biological agent. According to the application, the miR-663 is screened out through a transcriptome sequencing technology, a cell function experiment and a Western blot experiment show that the miR-663 can obviously inhibit the occurrence of EEC hypoxia injury, the inhibition can be realized through a target gene CDKN2A, and a new thought is provided for the treatment of thin endometrium.

The invention relates to the technical field of OCT detection, and discloses an OCT-based endometrium detection and an analysis method thereof, which comprises the following steps of: acquiring an endometrium OCT image to be detected; transmitting the endometrial OCT image to a trained uterus detection model for identification to obtain image detection information; and obtaining an endometrial detection result according to the image detection information. The invention further discloses the OCT-based endometrium detection and analysis device, electronic equipment and a storage medium. According to the embodiment of the invention, the method comprises the steps: inputting an obtained OCT image into a trained uterus detection model, and carrying out the recognition training, so as to obtain a corresponding endometrial condition. The device can achieve the quick recognition of abnormal conditions through an image recognition mode, assists a doctor in better diagnosis, improves the detection efficiency, and reduces the missed diagnosis of the doctor.

The invention discloses a microbial marker for bovine endometritis. The microbial marker comprises the following microorganisms with remarkably increased abundance: Bacteriodetes, Elusimicrobia, Verrucomicrobia, Spirochaetae and Lentisphaerae. The microbial marker also comprises the following microorganisms with remarkably increased abundance: Akkermansia, biogas bacillus, CF231 and Oscillosporia.The microbial marker also comprises the following microorganisms with remarkably decreased abundance: Ureaplasma urealyticum, Butyrivibrio, Doria, Sphingomonas sp, Rothia and Streptococcus. The invention discloses an application of the microbial marker for bovine endometritis in preparation of a tool for early screening or prediction of bovine endometritis. The applicant performs 16S rRNA gene sequencing on microbial DNA of a uterine mucus sample, compares structural differences of uterine florae between healthy and sick dairy cows, and finds differences in microbial community composition ofthe uterine florae between the healthy and sick dairy cows. The result provides a theoretical basis for better prevention and treatment of clinical endometritis.

Present invention provides a method for diagnosing and prognosing endometrial cancer in easy-to-access isolated samples by detecting the level of expression of one or more proteins. In particular from uterine fluid samples. The invention also provides kits comprising means for detecting said proteins for use in the diagnosis and prognosis of the disease.

The invention belongs to the field of medical apparatuses, and particularly relates to a negative pressure endometrium sampler and a use method thereof. The negative pressure endometrium sampler comprises a negative pressure adsorption device, a pressure regulating device and a rotatable adsorption tube, wherein the rotatable adsorption tube comprises a rotating sleeve tube and an adsorption tubeassembly, the adsorption tube assembly comprises an adsorption tube and a protecting tube arranged outside the adsorption tube, scrapers and absorbing holes are peripherally distributed at one end away from the rotating sleeve tube, of the adsorption tube, one end of the rotating sleeve tube is connected with the pressure regulating tube, and the inner part of the other end of the rotating sleevetube and the outer wall of the adsorption tube are in cooperation and rotating connection through a bearing; a rotating block is arranged at the connecting end of the adsorption tube and the rotatingsleeve tube; a clamping block in movable connection is arranged between the protecting tube and the rotating block; the rotating block and the protecting tube can perform magnetic suction and adsorption; an end socket is arranged at the top of the adsorption tube; and when the clamping block is mounted, the protecting tube and the end surface of the end socket are in contact and cooperation. The device can remove liquid in a womb before endometrium scraping, so that the endometrium sampling quality can be improved.

In some aspects, the disclosure relates to methods for screening clinical samples for the presence of L-form bacteria associated with endometriosis and/or ovarian fibroid tumors. The disclosure is based, in part, on screening methods used to diagnose a subject as likely having or likely not having endometriosis and/or an ovarian fibroid tumor. In some embodiments, the disclosure relates to methods of treating endometriosis by administering an antibiotic to a subject that has been determined to be infected by one or more strains of L-form bacteria.

The invention relates to a bioactive scaffold for repairing endometrium and improving fertility. The scaffold comprises a substrate and bioactive factors contained by the substrate. Endogenous stem cells are recruited and captured by bioactive factors. The stem cells have pluripotency and play a role in immune regulation and control on a wound surface, thereby effectively promoting endometrial repairing and remarkably increasing the fertility rate. According to the invention, the endogenous stem cell homing means integrated with collection and capturing is employed to repair the damaged endometrium so as to solve problems of intrauterine adhesion, reduced fertility rate and the like caused by a hysteroscope operation, thereby eliminating the potential safety hazards caused by usage of exogenous cells in the traditional repair material. The adopted raw materials have high biocompatibility; the preparation process is simple; exogenous cells are not contained; and the biological safety ishigh.

The invention discloses a molecular diagnosis and treatment preparation for endometriosis as well as a preparation method and application thereof. The preparation comprises: 1) an effect component, namely a diagnostic compound and/or a drug for treating endometriosis; 2) a targeting component, namely a polypeptide with targeting recognition capability; the polypeptide comprises a polypeptide formed by combining one or more of the following sequences, or a derivative of the polypeptide formed by combining one or more of the following sequences: SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6. The method is suitable for diagnosis and/or treatment of human endometriosis diseases, and can also be used as a research tool of an endometriosis modeling experimental animal.